Century Historical Balance Sheet

IPSC Stock

USD 0.70 0.01 1.41%

Trend analysis of Century Therapeutics balance sheet accounts such as Total Current Liabilities of 15.3 M or Total Stockholder Equity of 192.9 M provides information on Century Therapeutics' total assets, liabilities, and equity, which is the actual value of Century Therapeutics to its prevalent stockholders. By breaking down trends over time using Century Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Century Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Century Therapeutics is a good buy for the upcoming year.

Century Therapeutics Inventory

(213,750)

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Century Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Century Stock refer to our How to Trade Century Stock guide.

About Century Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Century Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Century Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Century Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Century currently owns. An asset can also be divided into two categories, current and non-current.

Century Therapeutics Balance Sheet Chart

At present, Century Therapeutics' Other Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Liabilities is expected to grow to about 212.3 M, whereas Other Current Liabilities is forecasted to decline to about 7.9 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Century Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Century Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Century Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Century Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Century Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Century Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Century Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade Century Stock refer to our How to Trade Century Stock guide.At present, Century Therapeutics' Other Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Liabilities is expected to grow to about 212.3 M, whereas Other Current Liabilities is forecasted to decline to about 7.9 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	10.2M	9.2M	8.3M	7.9M
Total Assets	486.5M	360.7M	324.6M	352.6M

Other Current Liab Total Assets

Century Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Long Term Debt	Inventory	Other Current Assets	Total Liab	Intangible Assets	Property Plant Equipment	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total
Total Assets		0.93	0.94	0.87	-0.17	0.91	-0.71	0.7	0.85	0.92	0.79	0.85	0.88	0.96	-0.25	-0.27	-0.43	0.3	-0.28	-0.31	-0.19	-0.43	-0.25	-0.25	-0.22	0.12
Other Current Liab	0.93		0.99	0.68	-0.4	0.95	-0.9	0.62	0.88	1.0	0.6	0.93	0.97	0.98	-0.55	-0.56	-0.55	0.54	-0.56	-0.6	-0.5	-0.58	-0.53	-0.4	-0.53	0.37
Total Current Liabilities	0.94	0.99		0.66	-0.41	0.98	-0.88	0.71	0.93	0.99	0.6	0.96	0.93	0.99	-0.56	-0.57	-0.56	0.56	-0.57	-0.61	-0.5	-0.59	-0.54	-0.41	-0.54	0.37
Total Stockholder Equity	0.87	0.68	0.66		0.12	0.61	-0.38	0.45	0.51	0.65	0.88	0.48	0.67	0.72	0.22	0.15	-0.18	-0.07	0.19	0.16	0.24	-0.19	0.19	0.03	0.22	-0.32
Other Liab	-0.17	-0.4	-0.41	0.12		-0.45	0.55	-0.38	-0.44	-0.44	0.21	-0.38	-0.35	-0.3	0.8	0.86	0.75	-0.94	0.76	0.72	0.74	0.72	0.82	0.87	0.75	-0.28
Accounts Payable	0.91	0.95	0.98	0.61	-0.45		-0.84	0.83	0.98	0.95	0.59	0.96	0.85	0.97	-0.56	-0.57	-0.56	0.58	-0.57	-0.59	-0.51	-0.57	-0.55	-0.44	-0.54	0.35
Cash	-0.71	-0.9	-0.88	-0.38	0.55	-0.84		-0.47	-0.79	-0.91	-0.42	-0.86	-0.89	-0.86	0.71	0.76	0.44	-0.65	0.72	0.76	0.79	0.59	0.73	0.46	0.79	-0.48
Other Assets	0.7	0.62	0.71	0.45	-0.38	0.83	-0.47		0.88	0.63	0.48	0.74	0.43	0.69	-0.36	-0.36	-0.48	0.45	-0.36	-0.33	-0.24	-0.39	-0.35	-0.42	-0.27	0.14
Long Term Debt	0.85	0.88	0.93	0.51	-0.44	0.98	-0.79	0.88		0.89	0.51	0.96	0.75	0.91	-0.57	-0.58	-0.56	0.57	-0.59	-0.62	-0.53	-0.6	-0.56	-0.43	-0.56	0.37
Inventory	0.92	1.0	0.99	0.65	-0.44	0.95	-0.91	0.63	0.89		0.57	0.94	0.96	0.98	-0.58	-0.6	-0.58	0.58	-0.6	-0.64	-0.54	-0.61	-0.57	-0.43	-0.57	0.39
Other Current Assets	0.79	0.6	0.6	0.88	0.21	0.59	-0.42	0.48	0.51	0.57		0.48	0.57	0.68	0.25	0.21	0.15	-0.19	0.26	0.23	0.18	0.09	0.24	0.19	0.19	-0.25
Total Liab	0.85	0.93	0.96	0.48	-0.38	0.96	-0.86	0.74	0.96	0.94	0.48		0.85	0.95	-0.64	-0.62	-0.52	0.56	-0.67	-0.7	-0.58	-0.54	-0.62	-0.4	-0.62	0.54
Intangible Assets	0.88	0.97	0.93	0.67	-0.35	0.85	-0.89	0.43	0.75	0.96	0.57	0.85		0.93	-0.5	-0.54	-0.49	0.49	-0.55	-0.57	-0.48	-0.55	-0.53	-0.37	-0.51	0.33
Property Plant Equipment	0.96	0.98	0.99	0.72	-0.3	0.97	-0.86	0.69	0.91	0.98	0.68	0.95	0.93		-0.46	-0.48	-0.47	0.45	-0.49	-0.53	-0.42	-0.52	-0.46	-0.32	-0.46	0.31
Net Tangible Assets	-0.25	-0.55	-0.56	0.22	0.8	-0.56	0.71	-0.36	-0.57	-0.58	0.25	-0.64	-0.5	-0.46		0.94	0.68	-0.91	0.97	0.96	0.9	0.62	0.94	0.71	0.92	-0.78
Property Plant And Equipment Net	-0.27	-0.56	-0.57	0.15	0.86	-0.57	0.76	-0.36	-0.58	-0.6	0.21	-0.62	-0.54	-0.48	0.94		0.69	-0.92	0.96	0.95	0.93	0.76	0.99	0.75	0.95	-0.56
Net Debt	-0.43	-0.55	-0.56	-0.18	0.75	-0.56	0.44	-0.48	-0.56	-0.58	0.15	-0.52	-0.49	-0.47	0.68	0.69		-0.84	0.69	0.68	0.46	0.86	0.66	0.77	0.52	-0.28
Retained Earnings	0.3	0.54	0.56	-0.07	-0.94	0.58	-0.65	0.45	0.57	0.58	-0.19	0.56	0.49	0.45	-0.91	-0.92	-0.84		-0.89	-0.86	-0.79	-0.77	-0.9	-0.82	-0.82	0.47
Non Current Assets Total	-0.28	-0.56	-0.57	0.19	0.76	-0.57	0.72	-0.36	-0.59	-0.6	0.26	-0.67	-0.55	-0.49	0.97	0.96	0.69	-0.89		0.98	0.89	0.67	0.98	0.71	0.91	-0.74
Non Currrent Assets Other	-0.31	-0.6	-0.61	0.16	0.72	-0.59	0.76	-0.33	-0.62	-0.64	0.23	-0.7	-0.57	-0.53	0.96	0.95	0.68	-0.86	0.98		0.93	0.74	0.94	0.63	0.95	-0.74
Cash And Short Term Investments	-0.19	-0.5	-0.5	0.24	0.74	-0.51	0.79	-0.24	-0.53	-0.54	0.18	-0.58	-0.48	-0.42	0.9	0.93	0.46	-0.79	0.89	0.93		0.63	0.9	0.56	1.0	-0.64
Net Receivables	-0.43	-0.58	-0.59	-0.19	0.72	-0.57	0.59	-0.39	-0.6	-0.61	0.09	-0.54	-0.55	-0.52	0.62	0.76	0.86	-0.77	0.67	0.74	0.63		0.69	0.64	0.67	-0.16
Common Stock Total Equity	-0.25	-0.53	-0.54	0.19	0.82	-0.55	0.73	-0.35	-0.56	-0.57	0.24	-0.62	-0.53	-0.46	0.94	0.99	0.66	-0.9	0.98	0.94	0.9	0.69		0.76	0.91	-0.6
Common Stock Shares Outstanding	-0.25	-0.4	-0.41	0.03	0.87	-0.44	0.46	-0.42	-0.43	-0.43	0.19	-0.4	-0.37	-0.32	0.71	0.75	0.77	-0.82	0.71	0.63	0.56	0.64	0.76		0.57	-0.29
Short Term Investments	-0.22	-0.53	-0.54	0.22	0.75	-0.54	0.79	-0.27	-0.56	-0.57	0.19	-0.62	-0.51	-0.46	0.92	0.95	0.52	-0.82	0.91	0.95	1.0	0.67	0.91	0.57		-0.66
Non Current Liabilities Total	0.12	0.37	0.37	-0.32	-0.28	0.35	-0.48	0.14	0.37	0.39	-0.25	0.54	0.33	0.31	-0.78	-0.56	-0.28	0.47	-0.74	-0.74	-0.64	-0.16	-0.6	-0.29	-0.66

Click cells to compare fundamentals

Century Therapeutics Account Relationship Matchups

Century Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	106.8M	437.4M	486.5M	360.7M	324.6M	352.6M
Other Current Liab	3.8M	6.4M	10.2M	9.2M	8.3M	7.9M
Total Current Liabilities	12.1M	15.7M	29.8M	17.8M	16.1M	15.3M
Total Stockholder Equity	(106.4M)	396.2M	302.7M	184.8M	212.5M	192.9M
Accounts Payable	8.1M	7.6M	5.5M	2.7M	2.5M	2.3M
Cash	27.2M	56.4M	84.3M	47.3M	54.4M	44.2M
Other Assets	2.1M	3.5M	3.2M	1.0	0.9	0.86
Other Current Assets	3.0M	5.0M	3.4M	4.3M	4.9M	4.0M
Total Liab	213.2M	41.1M	183.8M	175.9M	158.3M	212.3M
Property Plant And Equipment Net	15.4M	69.8M	111.7M	92.1M	105.9M	64.1M
Net Debt	(5.7M)	(33.0M)	(34.9M)	847K	974.1K	1.0M
Retained Earnings	(292.3M)	(388.2M)	(519.1M)	(655.8M)	(590.2M)	(619.7M)
Non Current Assets Total	28.0M	209.2M	166.8M	183.7M	211.3M	130.8M
Non Currrent Assets Other	1.2M	3.5M	3.2M	2.5M	2.9M	2.4M
Cash And Short Term Investments	75.8M	222.9M	315.5M	172.7M	198.6M	191.0M
Net Receivables	908K	250K	780K	665K	764.8K	599.7K
Short Term Investments	48.5M	166.4M	231.2M	125.4M	144.2M	134.0M
Liabilities And Stockholders Equity	106.8M	437.4M	486.5M	360.7M	414.8M	326.1M
Non Current Liabilities Total	201.1M	25.5M	154.0M	158.1M	142.3M	114.9M
Capital Lease Obligations	11.9M	14.6M	39.2M	48.2M	55.4M	58.2M
Other Stockholder Equity	185.9M	785.0M	824.3M	840.4M	966.5M	572.6M
Net Invested Capital	(96.7M)	405.1M	313.0M	184.8M	212.5M	157.1M
Long Term Investments	1.1M	135.9M	51.9M	89.1M	102.5M	62.0M
Property Plant And Equipment Gross	15.4M	58.0M	82.8M	114.9M	132.2M	138.8M
Total Current Assets	78.8M	228.2M	319.7M	177.0M	203.5M	195.3M
Net Working Capital	66.7M	212.5M	289.9M	159.1M	183.0M	178.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
C	Citigroup
GM	General Motors

When determining whether Century Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Century Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Century Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Century Therapeutics Stock:

How To Invest In Century

Details

Is Century Stock a good investment?

Details

What is Century Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Century Stock refer to our How to Trade Century Stock guide.

You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Century Therapeutics. If investors know Century will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Century Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.83)

Revenue Per Share

0.037

Quarterly Revenue Growth

4.345

Return On Assets

(0.21)

Return On Equity

(0.63)

The market value of Century Therapeutics is measured differently than its book value, which is the value of Century that is recorded on the company's balance sheet. Investors also form their own opinion of Century Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Century Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Century Therapeutics' market value can be influenced by many factors that don't directly affect Century Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Century Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Century Historical Balance Sheet

Century Therapeutics Inventory

(213,750)

About Century Balance Sheet Analysis

Century Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Century Therapeutics balance sheet Correlations

Century Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Century Therapeutics balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Inventory	+ 1.0	Other Current Liab
Short Term Investments	+ 1.0	Cash And Short Term Investments
Total Current Liabilities	+ 0.99	Other Current Liab
Inventory	+ 0.99	Total Current Liabilities
Property Plant Equipment	+ 0.99	Total Current Liabilities
Common Stock Total Equity	+ 0.99	Property Plant And Equipment Net

Retained Earnings	- 0.94	Other Liab
Retained Earnings	- 0.92	Property Plant And Equipment Net
Retained Earnings	- 0.91	Net Tangible Assets
Inventory	- 0.91	Cash
Common Stock Total Equity	- 0.9	Retained Earnings
Cash	- 0.9	Other Current Liab